7,151 Shares in AstraZeneca Plc $AZN Purchased by Moors & Cabot Inc.

Moors & Cabot Inc. purchased a new stake in AstraZeneca Plc (NYSE:AZN – Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 7,151 shares of the company’s stock, valued at approximately $1,155,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. William Blair Investment Management LLC bought a new stake in shares of AstraZeneca in the third quarter worth $90,809,000. Allworth Financial LP boosted its holdings in AstraZeneca by 313.0% during the third quarter. Allworth Financial LP now owns 33,413 shares of the company’s stock worth $5,395,000 after purchasing an additional 25,322 shares during the last quarter. GKV Capital Management Co. Inc. boosted its holdings in AstraZeneca by 14.8% during the third quarter. GKV Capital Management Co. Inc. now owns 12,905 shares of the company’s stock worth $2,100,000 after purchasing an additional 1,660 shares during the last quarter. Fisher Asset Management LLC grew its position in AstraZeneca by 3.2% in the third quarter. Fisher Asset Management LLC now owns 11,501,748 shares of the company’s stock valued at $1,857,187,000 after purchasing an additional 355,456 shares in the last quarter. Finally, Legacy Trust bought a new position in AstraZeneca in the third quarter valued at $254,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

AZN has been the topic of several recent research reports. Deutsche Bank upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, September 15th. Royal Bank Of Canada started coverage on shares of AstraZeneca in a research report on Tuesday, September 8th. They set an “outperform” rating on the stock. CICC Research began coverage on shares of AstraZeneca in a research note on Sunday, August 23rd. They set an “outperform” rating and a $198.00 price objective for the company. Weiss Ratings upgraded AstraZeneca from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday, October 26th. Finally, Nordea Equity Research upgraded AstraZeneca from a “sell” rating to a “buy” rating in a report on Tuesday, October 13th. Sixteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, AstraZeneca has a consensus rating of “Moderate Buy” and an average price target of $206.67.

View Our Latest Report on AZN

AstraZeneca Trading Up 0.1%

Shares of AstraZeneca stock opened at $184.66 on Monday. AstraZeneca Plc has a 12-month low of $153.41 and a 12-month high of $212.71. The stock has a market cap of $286.40 billion, a P/E ratio of 26.12, a P/E/G ratio of 1.43 and a beta of 0.24. The company has a quick ratio of 0.79, a current ratio of 1.01 and a debt-to-equity ratio of 0.51. The business’s 50 day moving average is $168.82 and its 200-day moving average is $180.20.

AstraZeneca (NYSE:AZN – Get Free Report) last released its quarterly earnings data on Friday, October 30th. The company reported $2.79 EPS for the quarter, beating the consensus estimate of $2.60 by $0.19. AstraZeneca had a return on equity of 31.85% and a net margin of 17.68%. The company had revenue of $16.21 billion during the quarter, compared to the consensus estimate of $16 billion. During the same quarter in the prior year, the firm posted $2.38 EPS. The firm’s revenue for the quarter was up 6.5% compared to the same quarter last year. Equities research analysts predict that AstraZeneca Plc will post 10.22 earnings per share for the current fiscal year.

AstraZeneca Profile

(Free Report)

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.

Further Reading

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca Plc (NYSE:AZN – Free Report).

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.